Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Glioblastoma 5Gliosarcoma 4Central Nervous System Neoplasms 4Precancerous Conditions 2Oligodendroglioma 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Brain Neoplasms 2Astrocytoma 2Anemia, Refractory, with Excess of Blasts 2Thrombocytopenia 1Squamous Intraepithelial Lesions 1Rectal Neoplasms 1Prostatic Neoplasms 1Prolactinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pituitary Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1

Interventions

pasireotide 7Cabergoline 7Temozolomide 3Propofol 3Hydrocortisone 3Dexmedetomidine 3lanreotide 2Sevoflurane 2Saline Solution 2Rosiglitazone 2Proton Therapy 2Octreotide 2Dexamethasone 2Desflurane 2pegvisomant 1parecoxib 1lutetium Lu 177 dotatate 1loxoprofen 1farletuzumab 1entinostat 1corticorelin ovine 1antineoplaston AS 2-1 1antineoplaston A10 1Yoga 1Trimethoprim 1Transcranial Magnetic Stimulation 1Tranexamic Acid 1Tramadol 1Thyrotropin-Releasing Hormone 1TBR-760 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pituitary Neoplasms × DNA Methylation × Clear all
NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
CNSEndocrine

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡